Hyderabad, Nov 16: Dr. Reddy’s Laboratories has announced the launch of Nerivio, a wearable therapy device approved by the US Food and Drug Administration (USFDA) for drug-free management of migraines.
Migraine, a global health challenge affecting around 30% of adults on 15 or more days per month, impacts 1.7 to 4% of the population. The condition has a disproportionate impact on women, constituting approximately 60% of the 213 million migraine sufferers in India alone.
Nerivio, a prescription-based non-invasive device, is designed for acute and preventive treatment of migraines in adults and adolescents aged 12 years and above. Worn on the upper arm, the device should be used within 60 minutes of headache onset for acute treatment or every alternate day for prevention.
Utilizing the Remote Electrical Neuromodulation (REN) mechanism, Nerivio activates conditioned pain modulation by stimulating nerve endings. This triggers a natural pain-relieving process in the brainstem, providing a global effect of pain inhibition that impacts the original source of migraine pain.
M.V. Ramana, CEO of Branded Markets (India and Emerging Markets) at Dr. Reddy’s, stated, “Nerivio is a USFDA-approved, drug-free, noninvasive, first-of-its-kind product for migraine in India and offers a favorable safety profile. We believe this product meets a genuine unmet clinical need among migraine patients.”
He added, “The roll-out of Nerivio marks our entry into digital therapeutics—an area seeing increasing adoption due to its potential to reduce pill burden and decrease dependency on non-specific medication in chronic or hard-to-treat diseases.”
Nerivio is clinically proven and safe, suitable for various patient groups, including those who prefer drug-free options, individuals with contraindications to medications, or poor medication tolerance. Studies have demonstrated its efficacy in treating associated symptoms in migraines, such as nausea and vomiting.
Dr. Reddy’s has also entered into an exclusive agreement for the commercial marketing and distribution of Nerivio in several European countries, including Germany, France, Italy, Spain, and the UK.
